These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20618337)

  • 1. Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study.
    Richardson PG; Chanan-Khan AA; Alsina M; Albitar M; Berman D; Messina M; Mitsiades CS; Anderson KC
    Br J Haematol; 2010 Aug; 150(4):438-45. PubMed ID: 20618337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.
    Richardson PG; Badros AZ; Jagannath S; Tarantolo S; Wolf JL; Albitar M; Berman D; Messina M; Anderson KC
    Br J Haematol; 2010 Aug; 150(4):428-37. PubMed ID: 20618338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study.
    Richardson PG; Chanan-Khan AA; Lonial S; Krishnan AY; Carroll MP; Alsina M; Albitar M; Berman D; Messina M; Anderson KC
    Br J Haematol; 2011 Jun; 153(6):729-40. PubMed ID: 21534941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tanespimycin pharmacokinetics: a randomized dose-escalation crossover phase 1 study of two formulations.
    Burris HA; Berman D; Murthy B; Jones S
    Cancer Chemother Pharmacol; 2011 May; 67(5):1045-54. PubMed ID: 20652703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
    Modi S; Stopeck AT; Gordon MS; Mendelson D; Solit DB; Bagatell R; Ma W; Wheler J; Rosen N; Norton L; Cropp GF; Johnson RG; Hannah AL; Hudis CA
    J Clin Oncol; 2007 Dec; 25(34):5410-7. PubMed ID: 18048823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia.
    Kaufmann SH; Karp JE; Litzow MR; Mesa RA; Hogan W; Steensma DP; Flatten KS; Loegering DA; Schneider PA; Peterson KL; Maurer MJ; Smith BD; Greer J; Chen Y; Reid JM; Ivy SP; Ames MM; Adjei AA; Erlichman C; Karnitz LM
    Haematologica; 2011 Nov; 96(11):1619-26. PubMed ID: 21791475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tanespimycin as antitumor therapy.
    Dimopoulos MA; Mitsiades CS; Anderson KC; Richardson PG
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):17-22. PubMed ID: 21454186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors.
    Saif MW; Erlichman C; Dragovich T; Mendelson D; Toft D; Burrows F; Storgard C; Von Hoff D
    Cancer Chemother Pharmacol; 2013 May; 71(5):1345-55. PubMed ID: 23564374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.
    Kummar S; Gutierrez ME; Gardner ER; Chen X; Figg WD; Zajac-Kaye M; Chen M; Steinberg SM; Muir CA; Yancey MA; Horneffer YR; Juwara L; Melillo G; Ivy SP; Merino M; Neckers L; Steeg PS; Conley BA; Giaccone G; Doroshow JH; Murgo AJ
    Eur J Cancer; 2010 Jan; 46(2):340-7. PubMed ID: 19945858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.
    Erlichman C
    Expert Opin Investig Drugs; 2009 Jun; 18(6):861-8. PubMed ID: 19466875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma.
    Pacey S; Gore M; Chao D; Banerji U; Larkin J; Sarker S; Owen K; Asad Y; Raynaud F; Walton M; Judson I; Workman P; Eisen T
    Invest New Drugs; 2012 Feb; 30(1):341-9. PubMed ID: 20683637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.
    Hendrickson AE; Oberg AL; Glaser G; Camoriano JK; Peethambaram PP; Colon-Otero G; Erlichman C; Ivy SP; Kaufmann SH; Karnitz LM; Haluska P
    Gynecol Oncol; 2012 Feb; 124(2):210-5. PubMed ID: 22047770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers.
    Ramanathan RK; Egorin MJ; Eiseman JL; Ramalingam S; Friedland D; Agarwala SS; Ivy SP; Potter DM; Chatta G; Zuhowski EG; Stoller RG; Naret C; Guo J; Belani CP
    Clin Cancer Res; 2007 Mar; 13(6):1769-74. PubMed ID: 17363531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study.
    Weigel BJ; Blaney SM; Reid JM; Safgren SL; Bagatell R; Kersey J; Neglia JP; Ivy SP; Ingle AM; Whitesell L; Gilbertson RJ; Krailo M; Ames M; Adamson PC
    Clin Cancer Res; 2007 Mar; 13(6):1789-93. PubMed ID: 17363534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.
    Vaishampayan UN; Burger AM; Sausville EA; Heilbrun LK; Li J; Horiba MN; Egorin MJ; Ivy P; Pacey S; Lorusso PM
    Clin Cancer Res; 2010 Jul; 16(14):3795-804. PubMed ID: 20525756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.
    Modi S; Stopeck A; Linden H; Solit D; Chandarlapaty S; Rosen N; D'Andrea G; Dickler M; Moynahan ME; Sugarman S; Ma W; Patil S; Norton L; Hannah AL; Hudis C
    Clin Cancer Res; 2011 Aug; 17(15):5132-9. PubMed ID: 21558407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma.
    Siegel D; Jagannath S; Vesole DH; Borello I; Mazumder A; Mitsiades C; Goddard J; Dunbar J; Normant E; Adams J; Grayzel D; Anderson KC; Richardson P
    Leuk Lymphoma; 2011 Dec; 52(12):2308-15. PubMed ID: 21851215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.
    Richardson PG; Mitsiades CS; Laubach JP; Lonial S; Chanan-Khan AA; Anderson KC
    Br J Haematol; 2011 Feb; 152(4):367-79. PubMed ID: 21219297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
    Solit DB; Ivy SP; Kopil C; Sikorski R; Morris MJ; Slovin SF; Kelly WK; DeLaCruz A; Curley T; Heller G; Larson S; Schwartz L; Egorin MJ; Rosen N; Scher HI
    Clin Cancer Res; 2007 Mar; 13(6):1775-82. PubMed ID: 17363532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia.
    Lancet JE; Gojo I; Burton M; Quinn M; Tighe SM; Kersey K; Zhong Z; Albitar MX; Bhalla K; Hannah AL; Baer MR
    Leukemia; 2010 Apr; 24(4):699-705. PubMed ID: 20111068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.